Kiev, Ukraine (PRWEB) July 11, 2008
Ukrainian company, Ekomed LLC, published clinical study of phytoconcentrates Dzherelo (Immunoxel), Lizorm and Svitanok utilized as an adjunct immunotherapy against multi-drug (MDR-TB), (XDR-TB), and in patients with concomitant HIV and Mycobacterium tuberculosis infections.
The study appeared in the present problem of International Journal of Biomedical and Pharmaceutical Sciences (Vol. 2 Pages 59-64, 2008). Abstract of the paper can be found online at: http://www.globalsciencebooks.info/JournalsSup/08IJBPS_2_1.html
Open-label, salvage anti-tuberculosis therapy (ATT) combined with Dzherelo (Immunoxel), Svitanok, and Lizorm- over-the-counter immunomodulators from medicinal plants - was conducted in 20 Ukrainian patients with late-stage pulmonary TB. In this study seven patients had XDR-TB and the remaining had MDR-TB. Among latter two patients had HIV co-infection but five other AIDS patients had drug-sensitive TB. Patients hospitalized in the TB dispensary were treated under directly observed therapy (DOT) until repeated negative culture conversion and recuperation from radiological and clinical symptoms. The average duration of therapy was 16.2 ± 5.2 weeks (range 10.6-30.3 median 16). The mean time to bacterial clearance was four.four ± 1.8 weeks (range 1.3-8.9, median 4.three). All patients (95%), except 1, gained weight, ranging between 3-17 kg with average 8.7 kg (P=.000009). The liver function tests revealed that the level of total bilirubin had improved from 15.five to 11.6 μmol/L (P=.009). Alanine transaminase (ALT) came down to normal from 53.1 IU/L to 30.4 IU/L level (P=.001). Hemoglobin levels increased from 103.2 to 117.3 g/L (P=.00005). Inflammation-linked, elevated leukocyte counts returned back to typical from 8.9 to 6.9 × 109 cells/L (P=.003). CD4 T lymphocyte counts in HIV patients have increased from average 371 cells at baseline to 566 cells - an enhance equal to 52% (P=.07). The absolute numbers of CD8+ T-lymphocytes appeared to decline but no statistical significance has been reached (P=.1). The improve in CD4 cells and decline in CD8 cells resulted in almost doubled ratio of CD4/CD8 cells, i.e., from baseline .475 to .848 at the end of therapy (P=.03). Patients recovered clinically and radiologically and had been hence discharged from the hospital right after 4 months on average.
These findings support prior trials indicating clinical benefit of adding immunomodulators to TB treatment regimens. The combination of ATT with botanical preparations enhances the clinical efficacy of DOT and is secure and beneficial even to patients with poor prognosis due to drug resistance and/or co-infection with HIV. This distinctive combination results in significantly shortened duration of treatment and is far more price-efficient than ATT alone.
Dzherelo, Lizorm and Svitanok are extracts from plants grown in Ukraine that have been utilized as food or folk medicine considering that time immemorial. Becoming derived from botanical sources and with established record of safety they have been approved by the Ministry of Well being of Ukraine in 1997 as dietary supplements and as a functional food in 2006.
Over 9 million new circumstances of TB occur each and every year worldwide. In the United States alone, it is estimated that 10-15 million people are infected with the TB bacteria and 22,000 new instances happen each year. Tuberculosis is spread from person to person by breathing infected air throughout close contact. Thus, everyone can get TB.
In spite of the overwhelming burden of TB, no new compounds were developed in last 40 years and current strains of TB are becoming resistant to existing drugs. Multidrug-resistant tuberculosis (MDR-TB) refers to organisms that are resistant to at least two of the first-line drugs, Izoniazid and Rifampicin. Far more lately, extensively (incredibly) drug resistant tuberculosis (XDR-TB) has emerged which is resistant to 3 or far more of the second-line treatment drugs. This emerging form of TB caused worldwide concern following lately reported outbreak in Kwazulu Natal province of South Africa where 52 of 53 patients with XDR-TB and HIV had died within 2 weeks from the time of diagnosis. Largely, simply because of HIV, a tremendous enhance in the incidence of TB is observed today and when these two infections are presented in tandem they are a lot more deadly than each 1 of them alone.
Scientific Director of Ekomed, Mr. Volodymyr Pylypchuk, commented: "Dzherelo and our other botanicals can be beneficial as immune adjuvants for therapy of tuberculosis and AIDS. What is crucial is that our study is the 1st ever study to show that 1 can treat successfully XDR TB - a condition which is commonly considered to be virtually incurable. In addition to medical problems Ekomed works on ecology projects. We have developed proprietary technologies that can potentially reverse global climate change and reduce greenhouse gas emissions, such as carbon dioxide, in ecologically friendly manner".
About Ekomed LLC
Founded in 1996, Ekomed is a privately-held organization based in Kiev, Ukraine. The business is the leading ethnobotanical company that manufactures over 26 distinct multiherbal preparations for a variety of wellness disorders. For far more details, please go to the business website at http://www.ekomed.com.ua
Media contact:
Volodymyr Pylypchuk
CEO and Scientific Director
Ekomed LLC
80-A Pravdy Avenue
pylypchuk @ bk.ru
http://www.ekomed.com.ua
###
, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.
0 comments:
Post a Comment